Minerva Surgical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 13, 2023 at 04:45 pm EST
Share
Minerva Surgical, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 11.97 million compared to USD 12.59 million a year ago. Net loss was USD 7.18 million compared to USD 11.33 million a year ago. Basic loss per share from continuing operations was USD 0.81 compared to USD 7.92 a year ago.
For the nine months, sales was USD 37.89 million compared to USD 36.49 million a year ago. Net loss was USD 27.21 million compared to USD 27.87 million a year ago. Basic loss per share from continuing operations was USD 3.49 compared to USD 19.48 a year ago.
Minerva Surgical, Inc. is a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women. It has established a product line of commercially available, minimally invasive alternatives to hysterectomy, which are designed to address the most common causes of Abnormal Uterine Bleeding (AUB) in most uterine anatomies. Its Minerva Surgical solutions can be used in a variety of medical treatment settings and aim to address the drawbacks associated with alternative treatment methods and to preserve the uterus by avoiding unnecessary hysterectomies. It offers a range of solutions, such as the Minerva ES Endometrial Ablation System (Minerva ES), Genesys HTA Endometrial Ablation System (Genesys HTA), Symphion Tissue Removal System (Symphion), and Resectr Tissue Resection Device (Resectr). Minerva ES is an endometrial ablation device that utilizes its PlasmaSense technology.